ANGLE PLC | MedPath

ANGLE's Parsortix System Shows Promise in Real-Time HER2 Status Monitoring for Breast Cancer Patients

2 months ago

• ANGLE plc has successfully completed development of two assays for AstraZeneca: an Androgen Receptor assay for prostate cancer and a DNA damage response micronuclei assay, positioning the company for large-scale clinical trials. • Results from Eisai's Phase 2 pilot study demonstrate that ANGLE's Parsortix-based HER2 assay can effectively measure changes in breast cancer patients' HER2 status over time, offering advantages over traditional tissue biopsies. • The liquid biopsy technology shows potential to identify patients who may benefit from HER2-targeted therapies despite initially testing negative via tissue biopsy, potentially expanding treatment options and improving patient outcomes.

ANGLE and Illumina's Dual DNA Analysis Improves Lung Cancer Biomarker Detection

6 months ago

• ANGLE plc and Illumina have successfully combined technologies for dual analysis of circulating tumor DNA (ctDNA) and circulating tumor cell DNA (CTC-DNA). • In a study of 27 lung cancer patients, combined analysis identified twice as many mutations compared to ctDNA analysis alone, enhancing biomarker detection. • The dual analysis workflow, utilizing Illumina's NGS platform, showed that CTC-DNA analysis could reveal mutations missed by ctDNA analysis, especially in treated patients. • Illumina has highlighted ANGLE's findings at a European Association for Cancer Research webinar, indicating the importance of this combined approach.